Increased wound-response revealed by proteomics of estrogen receptor-negative breast cancers

2008 ◽  
Vol 68 (S 01) ◽  
Author(s):  
H Neubauer ◽  
K Sotlar ◽  
D Wallwiener ◽  
MA Cahill ◽  
E Solomayer ◽  
...  
Keyword(s):  
Estrogen Receptor ◽  
Wound Response ◽  
Breast Cancers ◽  
Estrogen Receptor Negative

scholarly journals Patients with Early-Stage and Estrogen Receptor-Negative Breast Cancers: Young Age Does Link to Poor Outcomes

2019 ◽  
Vol 10 (12) ◽  
pp. 662-678
Author(s):  
Yanyan Xie ◽  
Lv Qing ◽  
Yao Wang ◽  
Yuting Zhou ◽  
Juanjuan Qiu ◽  
...  
Keyword(s):  
Estrogen Receptor ◽  
Early Stage ◽  
Young Age ◽  
Breast Cancers ◽  
Poor Outcomes ◽  
Estrogen Receptor Negative

scholarly journals Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15

2013 ◽  
Vol 15 (3) ◽  
Author(s):  
Jacqueline Lehmann-Che ◽  
Anne-Sophie Hamy ◽  
Raphaël Porcher ◽  
Marc Barritault ◽  
Fatiha Bouhidel ◽  
...  
Keyword(s):  
Estrogen Receptor ◽  
Breast Cancers ◽  
Molecular Apocrine ◽  
Estrogen Receptor Negative

Expression of steroids and HER2-neu receptors in breast tumors associated with BRCA1 gene mutations

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e22223-e22223
Author(s):  
N. A. Zarubina ◽  
V. D. Petrova ◽  
T. V. Sinkina ◽  
S. A. Terekhova ◽  
A. F. Lazarev ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Progesterone Receptor ◽  
Bilateral Breast Cancer ◽  
Gene Mutations ◽  
Brca1 Gene ◽  
Breast Tumors ◽  
Breast Cancers ◽  
Breast Carcinomas ◽  
Estrogen Receptor Negative

e22223 Background: Hereditary breast carcinomas that are attributable to BRCA1 mutations have their own morphological and immunohistochemical characteristics. This study was aimed to analyze the level of expression of steroids (estrogen and progesterone) and HER2-neu receptors in BRCA1 associated breast cancer. Methods: DNA patterns from 264 patients with hereditary breast cancers (breast cancer diagnosed at the age under 40; bilateral breast cancer; combination of breast and ovarian cancers; 2 and more breast cancers in blood relatives). All the patients were residents of the Altai Territory. BRCA1 gene mutations were registered in 34 patients (12.9%): 5382insC gene mutation - in 28 patients; 300A/C - in 2 patients; 4153del - in 3 patients; 185del - in 1 patient. The frequency of the BRCA1 5382insC allele mutation was 7.3; 300A/C - 0.52; 4153del - 0.26; 185del - 0.83. Immunohistochemical characteristics of BRCA1-associated breast tumors tissue from these patients were investigated. Results: 32 BRCA1-associated breast carcinomas were estrogen receptor- negative; 1 - week positive (H-score 50–100); 1 - moderate positive (H- score 100–200). 33 BRCA1-associated breast carcinomas were progesterone receptor- negative; 1 - positive (H-score 200 and more). HER2-negative were 31 BRCA1-associated breast carcinomas; 2 were week positive (HER2-neu +); 1 - was moderate positive (HER2-neu ++). Conclusion: BRCA1-associated beast carcinomas have been found to be more frequently estrogen receptor-, progesterone receptor-, and HER2- negative. These data show that hereditary breast cancer associated with BRCA1 gene mutations poses poor prognosis. No significant financial relationships to disclose.

scholarly journals Increased CpG methylation of the estrogen receptor gene in BRCA1-linked estrogen receptor-negative breast cancers

Oncogene ◽  
2002 ◽  
Vol 21 (46) ◽  
pp. 7034-7041 ◽  
Author(s):  
William B Archey ◽  
Kristen A McEachern ◽  
Mark Robson ◽  
Kenneth Offit ◽  
Susan AJ Vaziri ◽  
...  
Keyword(s):  
Estrogen Receptor ◽  
Receptor Gene ◽  
Cpg Methylation ◽  
Breast Cancers ◽  
Estrogen Receptor Gene ◽  
Estrogen Receptor Negative

scholarly journals Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers

2007 ◽  
Vol 9 (1) ◽  
Author(s):  
Mervi Jumppanen ◽  
Sofia Gruvberger-Saal ◽  
Päivikki Kauraniemi ◽  
Minna Tanner ◽  
Pär-Ola Bendahl ◽  
...  
Keyword(s):  
Estrogen Receptor ◽  
Patient Survival ◽  
Breast Cancers ◽  
Estrogen Receptor Negative

scholarly journals Circulating miRNAs in HER2-Positive and Triple Negative Breast Cancers: Potential Biomarkers and Therapeutic Targets

2020 ◽  
Vol 21 (18) ◽  
pp. 6750
Author(s):  
Ishita Gupta ◽  
Balsam Rizeq ◽  
Semir Vranic ◽  
Ala-Eddin Al Moustafa ◽  
Halema Al Farsi
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Triple Negative ◽  
Therapeutic Targets ◽  
Breast Cancers ◽  
Breast Cancer Patients ◽  
Circulating Mirnas ◽  
Her2 Positive ◽  
Cancer Disease ◽  
Estrogen Receptor Negative

Breast cancer is one of the most prevalent diseases among women worldwide and is highly associated with cancer-related mortality. Of the four major molecular subtypes, HER2-positive and triple-negative breast cancer (TNBC) comprise more than 30% of all breast cancers. While the HER2-positive subtype lacks estrogen and progesterone receptors and overexpresses HER2, the TNBC subtype lacks estrogen, progesterone and HER2 receptors. Although advances in molecular biology and genetics have substantially ameliorated breast cancer disease management, targeted therapies for the treatment of estrogen-receptor negative breast cancer patients are still restricted, particularly for TNBC. On the other hand, it has been demonstrated that microRNAs, miRNAs or small non-coding RNAs that regulate gene expression are involved in diverse biological processes, including carcinogenesis. Moreover, circulating miRNAs in serum/plasma are among the most promising diagnostic/therapeutic tools as they are stable and relatively easy to quantify. Various circulating miRNAs have been identified in several human cancers including specific breast cancer subtypes. This review aims to discuss the role of circulating miRNAs as potential diagnostic and prognostic biomarkers as well as therapeutic targets for estrogen-receptor negative breast cancers, HER2+ and triple negative.

Sign in / Sign up

Export Citation Format

Share Document